DE69202019D1 - Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS. - Google Patents

Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS.

Info

Publication number
DE69202019D1
DE69202019D1 DE69202019T DE69202019T DE69202019D1 DE 69202019 D1 DE69202019 D1 DE 69202019D1 DE 69202019 T DE69202019 T DE 69202019T DE 69202019 T DE69202019 T DE 69202019T DE 69202019 D1 DE69202019 D1 DE 69202019D1
Authority
DE
Germany
Prior art keywords
aids
medicament
treatment
manufacture
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69202019T
Other languages
English (en)
Inventor
David Frederick Horrobin
Michael David Winther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10698951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69202019(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Application granted granted Critical
Publication of DE69202019D1 publication Critical patent/DE69202019D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Junction Field-Effect Transistors (AREA)
  • Amplifiers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69202019T 1991-07-24 1992-07-20 Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS. Expired - Lifetime DE69202019D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919116054A GB9116054D0 (en) 1991-07-24 1991-07-24 Preparation of fatty acid medicaments

Publications (1)

Publication Number Publication Date
DE69202019D1 true DE69202019D1 (de) 1995-05-18

Family

ID=10698951

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69202019T Expired - Lifetime DE69202019D1 (de) 1991-07-24 1992-07-20 Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS.

Country Status (12)

Country Link
EP (1) EP0524796B1 (de)
JP (1) JPH05194244A (de)
KR (1) KR930001902A (de)
AT (1) ATE120954T1 (de)
AU (1) AU1968992A (de)
CA (1) CA2073913A1 (de)
DE (1) DE69202019D1 (de)
FI (1) FI923357A (de)
GB (1) GB9116054D0 (de)
IE (1) IE922250A1 (de)
NO (1) NO922936L (de)
ZA (1) ZA925562B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
GB9211229D0 (en) * 1992-05-27 1992-07-08 Efamol Holdings Fatty acid treatment
GB9304746D0 (en) * 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
GB9318611D0 (en) * 1993-09-08 1993-10-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US5856149A (en) * 1995-06-01 1999-01-05 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids
DE19611953A1 (de) * 1996-03-26 1997-10-02 Beiersdorf Ag Verwendung von ungesättigten Monocarbonsäuren gegen Superinfektionen
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
ES2209658B1 (es) * 2002-12-05 2005-10-01 Proyecto Empresarial Brudy, S.L. Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
EP1597978A1 (de) 2004-05-17 2005-11-23 Nutricia N.V. Synergie von GOS und polyfruktose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
CA2570208A1 (en) * 2004-06-22 2005-12-29 N.V. Nutricia Improvement of barrier integrity in hiv patients
JP2006282644A (ja) * 2005-04-05 2006-10-19 Idemitsu Kosan Co Ltd 疲労回復剤
MY163134A (en) 2006-03-15 2017-08-15 Suntory Holdings Ltd Composition containing riboflavin and sesamin-class compounds
WO2008094510A2 (en) 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
SG179481A1 (en) 2007-03-15 2012-04-27 Suntory Holdings Ltd Anti-fatigue agent
BRPI0813709A2 (pt) 2007-07-09 2015-01-06 Eastern Virginia Med School Derivados de nucleosídeo substituído com propriedades antiviral e antimicrobiana
CN101801370B (zh) * 2007-09-19 2013-06-12 三得利控股株式会社 含有芝麻素类和花生四烯酸类的组合物
JP2009073747A (ja) * 2007-09-19 2009-04-09 Suntory Ltd アラキドン酸を有効成分とする抗疲労剤
WO2020077420A1 (en) * 2018-10-16 2020-04-23 MOREIRA, Nivaldo José Extract of jatropha curcas seed oil

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen

Also Published As

Publication number Publication date
FI923357A0 (fi) 1992-07-23
AU1968992A (en) 1993-01-28
IE922250A1 (en) 1993-01-27
NO922936D0 (no) 1992-07-23
JPH05194244A (ja) 1993-08-03
CA2073913A1 (en) 1993-01-25
FI923357A (fi) 1993-01-25
ZA925562B (en) 1993-04-28
EP0524796B1 (de) 1995-04-12
EP0524796A1 (de) 1993-01-27
ATE120954T1 (de) 1995-04-15
KR930001902A (ko) 1993-02-22
GB9116054D0 (en) 1991-09-11
NO922936L (no) 1993-01-25

Similar Documents

Publication Publication Date Title
DE69202019D1 (de) Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS.
ATE133336T1 (de) Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ATE264676T1 (de) Verwendung von dha in der behandlung von dyslexie
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69010251D1 (de) Dentale Einheit zur Behandlung eines Wurzelkanals.
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE148628T1 (de) 5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten
ATE135223T1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DE3856052T2 (de) Anwendung des N-n-butyl-Derivates von Desoxynojirimycin zur Herstellung eines Arzneimittels zur Inhibierung von HIV-Virus
NO924637D0 (no) Fremgangsmaate ved forhindring av gjentilstopping av arterier
DE69100171T2 (de) Synergistische Kombination zur ophthalmischen Verwendung.
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE69610045T2 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
ATE76302T1 (de) Verwendung von einer immunstimulanten biologisten substanz zur herstellung eines medikaments zur behandlung des menschlichen immunschwaechevirus.
SE9403861D0 (sv) Novel medicinal use
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
DE68914886T2 (de) Mittel zur Behandlung von Raynaud's Krankheit.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE98127T1 (de) Verwendung von peroxidlipiden zur herstellung eines arzneimittels zur behandlung von kreislaufinsuffizienz bei lokaler applikation.
ATE56874T1 (de) Zubereitung zur behandlung und vorbeugung von diarrhoee bei menschen und tieren und verfahren zu deren herstellung.
ATE92763T1 (de) Mittel zur behandlung des parkinson-syndroms.

Legal Events

Date Code Title Description
8330 Complete renunciation